Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder
Shots:
- Neurocrine Biosciences has reported the first patient dosing with NBI-1070770, for which the company gained rights for the development & commercialization from Takeda, under the P-II clinical evaluation
- The multi-center, randomized, double-blind P-II (NBI-1070770-MDD2029) trial is to assess the efficacy, safety and tolerability of NBI-1070770 vs PBO to improve depression symptoms in major depressive disorder patients (n=72) across the US
- NBI-1070770 (oral) is a novel and selective negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor designed to treat depressive disorder
Ref: Neurocrine | Image: Neurocrine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
